319: Ignite Session 7A

Presentations:

• 1:00 PM – 1:05 PM Eastern Time

  Development of ACR Longitudinal Digital Quality Measures for Systemic Lupus Erythematosus: A Literature Review and Modified Delphi Consensus Study
  

  Ignite Speaker: Christie M. Bartels, MD, MS – University of Wisconsin School of Medicine and Public Health
• 1:05 PM – 1:10 PM Eastern Time

  Epidemiology and Outcomes of Emergency Department Visits in Systemic Lupus Erythematosus: Data from National Emergency Database Sample
  

  Ignite Speaker: Rashmi Dhital, MD – UC San Diego
• 1:10 PM – 1:15 PM Eastern Time

  Remission and Low Disease Activity Are Associated with Lower Health Care Costs in an International Inception Cohort of Patients with Systemic Lupus Erythematosus
  

  Ignite Speaker: Ann Clarke, MD, MSc – University of Calgary
• 1:15 PM – 1:20 PM Eastern Time

  Greater Social Vulnerability Associates with Greater Glucocorticoid Use in Patients with SLE
  

  Ignite Speaker: Avira Som, MD – Washington University School of Medicine in St. Louis
• 1:20 PM – 1:25 PM Eastern Time

  Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus
  

  Ignite Speaker: Emma Materne, MD – Massachusetts General Hospital
• 1:25 PM – 1:30 PM Eastern Time

  Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
  

  Ignite Speaker: Amit Saxena, MD – NYU School of Medicine
• 1:30 PM – 1:35 PM Eastern Time

  Attainment of Remission with Anifrolumab: A Post Hoc Analysis of Pooled TULIP-1 and TULIP-2 Datasets
  

  Ignite Speaker: Eric Morand, MD, PhD – Monash University
• 1:35 PM – 1:40 PM Eastern Time

  Regulatory T Cell Defects in SLE and Therapy with a Novel IL-2 Mutein: Phase 1 Clinical Results with Efavaleukin Alfa
  

  Ignite Speaker: Nandita Sarkar, PhD – Amgen
• 1:40 PM – 1:45 PM Eastern Time

  Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
  

  Ignite Speaker: Jiacai Cho, MBBS, MRCP, MMed – National University Hospital
• 1:45 PM – 1:50 PM Eastern Time

  Deucravacitinib Reduces Interferons, B Cell Pathways, and Serological Biomarkers of Systemic Lupus Disease Activity: Pharmacodynamic Analysis from the Phase 2 PAISLEY Study
  

  Ignite Speaker: Ian Catlett, PhD – Bristol Meyers Squibb